Virtus Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Virtus Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.69M	Buy	4,320 +722	+20%	+$491K	0.63%	15
2026 Q1	$2.78M	Buy	3,598 +2,677	+291%	+$2.05M	0.77%	3
2025 Q4	$711K	Buy	921 +69	+8%	+$46.9K	0.19%	160
2025 Q3	$479K	Hold	852	–	–	0.14%	208
2025 Q2	$447K	Buy	852 +366	+75%	+$204K	0.15%	198
2025 Q1	$308K	Buy	+486	New	+$334K	0.08%	239
2023 Q2	–	Sell	-601	Closed	-$494K	–	293
2023 Q1	$494K	Hold	601	–	–	0.35%	91
2022 Q4	$434K	Hold	601	–	–	0.29%	110
2022 Q3	$414K	Buy	+601	New	+$378K	0.19%	110
2018 Q1	–	Sell	-328	Closed	-$123K	–	351
2017 Q4	$123K	Sell	328 -6	-2%	-$2.43K	0.01%	456
2017 Q3	$149K	Sell	334 -39	-10%	-$18.6K	0.02%	441
2017 Q2	$183K	Sell	373 -51	-12%	-$22.3K	0.02%	430
2017 Q1	$164K	Buy	+424	New	+$157K	0.01%	424
2016 Q4	–	Sell	-1,608	Closed	-$646K	–	520
2016 Q3	$646K	Buy	+1,608	New	+$645K	0.04%	325

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Virtus Investment Advisers's REGN Position: Q2 2026 in Review

Virtus Investment Advisers increased its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, buying an estimated $491K and bringing the position to 4,320 shares worth $2.69M. The position accounts for 0.63% of the portfolio, ranked #15.

Virtus Investment Advisers first reported a position in REGN in Q3 2016 and has held it in 14 quarters since. The position peaked at $2.78M in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Virtus Investment Advisers held 4,320 shares of Regeneron Pharmaceuticals worth $2.69M as of Q2 2026.
Virtus Investment Advisers bought 722 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $491K.
Regeneron Pharmaceuticals made up 0.63% of Virtus Investment Advisers's portfolio in Q2 2026, its #15 holding.
Virtus Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 14 quarters since.
Virtus Investment Advisers's Regeneron Pharmaceuticals position peaked at $2.78M in Q1 2026.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.